JP2022530404A5 - - Google Patents
Info
- Publication number
- JP2022530404A5 JP2022530404A5 JP2021562979A JP2021562979A JP2022530404A5 JP 2022530404 A5 JP2022530404 A5 JP 2022530404A5 JP 2021562979 A JP2021562979 A JP 2021562979A JP 2021562979 A JP2021562979 A JP 2021562979A JP 2022530404 A5 JP2022530404 A5 JP 2022530404A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- antibody fragment
- fragment according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837214P | 2019-04-23 | 2019-04-23 | |
| US62/837,214 | 2019-04-23 | ||
| PCT/EP2020/060955 WO2020216697A1 (en) | 2019-04-23 | 2020-04-20 | Cd73 blocking antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530404A JP2022530404A (ja) | 2022-06-29 |
| JP2022530404A5 true JP2022530404A5 (enExample) | 2023-04-25 |
| JP7530913B2 JP7530913B2 (ja) | 2024-08-08 |
Family
ID=70456747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562979A Active JP7530913B2 (ja) | 2019-04-23 | 2020-04-20 | Ｃｄ７３遮断抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12528876B2 (enExample) |
| EP (1) | EP3959239A1 (enExample) |
| JP (1) | JP7530913B2 (enExample) |
| KR (1) | KR20220002959A (enExample) |
| CN (1) | CN113784981B (enExample) |
| AU (1) | AU2020260693A1 (enExample) |
| BR (1) | BR112021021224A2 (enExample) |
| CA (1) | CA3136698A1 (enExample) |
| IL (1) | IL286997A (enExample) |
| MX (1) | MX2021012769A (enExample) |
| SG (1) | SG11202111106WA (enExample) |
| TW (1) | TWI834867B (enExample) |
| WO (1) | WO2020216697A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016055609A1 (en) | 2014-10-10 | 2016-04-14 | Innate Pharma | Cd73 blockade |
| AU2018346447B2 (en) * | 2017-10-06 | 2025-06-19 | Innate Pharma | Restoration of T cell activity via the CD39/CD73 axis |
| CR20220317A (es) | 2020-01-03 | 2022-09-02 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| EP4084870A1 (en) | 2020-01-03 | 2022-11-09 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| KR20230050378A (ko) * | 2020-08-13 | 2023-04-14 | 이나뜨 파르마 에스.에이. | 항-cd73 항체를 사용하여 암을 치료하는 방법 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2487932A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| WO2016055609A1 (en) * | 2014-10-10 | 2016-04-14 | Innate Pharma | Cd73 blockade |
| JP6805142B2 (ja) * | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| EP3325967B1 (en) | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| WO2017064043A1 (en) * | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| EP3380519A1 (en) | 2015-11-23 | 2018-10-03 | Innate Pharma | Cd39 vascular isoform targeting agents |
| CA3007646A1 (en) | 2015-12-09 | 2017-06-15 | Bioatla, Llc | Humanized anti-cd73 antibodies |
| CA3009484A1 (en) * | 2015-12-22 | 2017-06-29 | Abbvie Stemcentrx Llc | Novel anti-mmp16 antibodies and methods of use |
| WO2017157948A1 (en) | 2016-03-14 | 2017-09-21 | Innate Pharma | Anti-cd39 antibodies |
| WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| AU2018235092B2 (en) | 2017-03-16 | 2024-09-19 | Innate Pharma | Compositions and methods for treating cancer |
| AU2018346447B2 (en) | 2017-10-06 | 2025-06-19 | Innate Pharma | Restoration of T cell activity via the CD39/CD73 axis |
| IL273440B1 (en) | 2017-11-15 | 2026-08-01 | Innate Pharma | Strengthening the effect of ATP release |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| TWI870353B (zh) | 2018-06-18 | 2025-01-21 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| KR20230050378A (ko) | 2020-08-13 | 2023-04-14 | 이나뜨 파르마 에스.에이. | 항-cd73 항체를 사용하여 암을 치료하는 방법 |
-
2020
- 2020-04-20 KR KR1020217036983A patent/KR20220002959A/ko active Pending
- 2020-04-20 JP JP2021562979A patent/JP7530913B2/ja active Active
- 2020-04-20 CA CA3136698A patent/CA3136698A1/en active Pending
- 2020-04-20 EP EP20721175.6A patent/EP3959239A1/en active Pending
- 2020-04-20 BR BR112021021224A patent/BR112021021224A2/pt unknown
- 2020-04-20 AU AU2020260693A patent/AU2020260693A1/en active Pending
- 2020-04-20 MX MX2021012769A patent/MX2021012769A/es unknown
- 2020-04-20 SG SG11202111106WA patent/SG11202111106WA/en unknown
- 2020-04-20 CN CN202080030003.3A patent/CN113784981B/zh active Active
- 2020-04-20 WO PCT/EP2020/060955 patent/WO2020216697A1/en not_active Ceased
- 2020-04-23 TW TW109113576A patent/TWI834867B/zh active
-
2021
- 2021-10-05 IL IL286997A patent/IL286997A/en unknown
- 2021-10-22 US US17/451,835 patent/US12528876B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7854016B2 (ja) | 腫瘍治療薬及びその応用 | |
| JP2024167313A5 (enExample) | ||
| JP2022079549A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2022093564A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2020515508A5 (enExample) | ||
| JP2021531254A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2013056885A5 (enExample) | ||
| JP2018512175A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2024102055A5 (enExample) | ||
| JP2020517239A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2023515223A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JP2025032102A5 (enExample) | ||
| JP2020500834A5 (enExample) | ||
| JP2020521478A5 (enExample) | ||
| RU2018129874A (ru) | Антитела против фактора свертывания xi |